Why Roivant Sciences Stock Is Perking Up Today
Shares of U.K.-based biotech Roivant Sciences (NASDAQ: ROIV) were up by 10.2% on heavy volume as of 10:21 a.m. ET Thursday. The drugmaker's stock is jumping in response to positive long-term data for its midstage ulcerative colitis therapy, RVT-3101.
RVT-3101 belongs to a novel class of biologic therapies known as anti-TL1A antibodies that have shown tremendous promise in the treatment of autoimmune disorders like ulcerative colitis and Crohn's disease (two common forms of inflammatory bowel disease). The therapy was originally part of 's (NYSE: PFE) homegrown portfolio. However, Pfizer offloaded a portion of RVT-3101's commercial rights to Roivant last December.
Ahead of the opening bell, Roivant announced that patients treated with the expected phase 3 dose of RVT-3101 in this large phase 2b trial exhibited a 36% clinical remission rate at week 56 (up from 29% at week 14). Even better, patients in the biomarker-positive population of the study exhibited a 43% clinical remission rate at week 56.
Source Fool.com
Pfizer Inc. Aktie
Die Pfizer Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Das Kursziel von 41 € für Pfizer Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 26.34 €.
